XenoPort, Inc. - Product Pipeline Review - H2 2011
Global Markets Direct
December 14, 2011 96 Pages - SKU: GMD6723951
|
|
XenoPort, Inc. - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “XenoPort, Inc. - Product Pipeline Review - H2 2011” provides data on the XenoPort, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, XenoPort, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from XenoPort, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope- XenoPort, Inc. - Brief XenoPort, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of XenoPort, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of XenoPort, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the XenoPort, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy- Evaluate XenoPort, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of XenoPort, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the XenoPort, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with XenoPort, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of XenoPort, Inc. and identify potential opportunities in those areas.
|
- XenoPort, Inc. Snapshot
- XenoPort, Inc. Overview
- Key Information
- Key Facts
- XenoPort, Inc. - Research and Development Overview
- Key Therapeutic Areas
- XenoPort, Inc. - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- XenoPort, Inc. - Pipeline Products Glance
- XenoPort, Inc. - Late Stage Pipeline
- Registration Filed Products/Combination Treatment Modalities
- Phase III Products/Combination Treatment Modalities
- XenoPort, Inc. Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- XenoPort, Inc. - Early Stage Pipeline Products
- Pre-Clinical Products/Combination Treatment Modalities
- XenoPort, Inc. - Drug Profiles
- Acomprosate Prodrug
- Arbaclofen Placarbil
- Horizant
- XP-21279
- XP21510
- XP23829
- XenoPort, Inc. - Pipeline Analysis
- XenoPort, Inc. - Pipeline Products by Therapeutic Class
- XenoPort, Inc. - Pipeline Products By Target
- XenoPort, Inc. - Pipeline Products by Route of Administration
- XenoPort, Inc. - Pipeline Products by Molecule Type
- XenoPort, Inc. - Recent Pipeline Updates
- XenoPort, Inc. - Discontinued Pipeline Products
- Discontinued Pipeline Product Profiles
- Horizant
- XP20925
- XenoPort, Inc. - Company Statement
- XenoPort, Inc. - Locations And Subsidiaries
- Head Office
- Company's Recent Developments
- XenoPort, Inc., Recent Developments
- Apr 25, 2011: XenoPort Announces FDA Agreement On Special Protocol Assessment For Pivotal Phase III Clinical Trial Of Arbaclofen Placarbil For Spasticity In MS Patients
- Mar 21, 2011: XenoPort Reports Results From Phase IIb Clinical Trial Of Arbaclofen Placarbil As Adjunctive Treatment For Patients With GERD
- Apr 13, 2011: XenoPort Announces Presentation Of Preclinical Data For XP23829 At 63rd Annual Meeting Of American Academy of Neurology
- Aug 09, 2011: GSK And XenoPort Submit Supplemental New Drug Application To FDA For Horizant In Postherpetic Neuralgia
- Apr 06, 2011: GlaxoSmithKline And XenoPort Receive FDA Approval For Horizant
- Financial Deals Landscape
- XenoPort, Inc., Deals Summary
- XenoPort, Inc., Pharmaceuticals & Healthcare, Deal Details
- Venture Financing
- XenoPort Secures $25 Million In Series D Financing
- XenoPort Secures $37 Million In Financing
- Partnerships
- XenoPort Amends Its Agreement With GlaxoSmithKline For Horizant
- XenoPort Enters Into Co-Promotion Agreement With GlaxoSmithKline For Solzira
- XenoPort Enters Into A Co-Development Agreement With Pfizer
- Licensing Agreements
- XenoPort Enters Into Licensing Agreement With Xanodyne
- Astellas Pharma Enters Into Licensing Agreement With XenoPort
- Equity Offering
- XenoPort Prices An Underwritten Public Offering Of $31 Million
- XenoPort Completes Public Offering Of $78.9 Million
- XenoPort Completes Initial Public Offering Of $52.6 Million
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- XenoPort, Inc., Key Information
- XenoPort, Inc., Key Facts
- XenoPort, Inc. - Pipeline by Therapy Area and Indication, H2 2011
- XenoPort, Inc. - Pipeline by Stage of Development, H2 2011
- XenoPort, Inc. - Monotherapy Products in Pipeline, H2 2011
- XenoPort, Inc. - Filed, H2 2011
- XenoPort, Inc. - Phase III, H2 2011
- XenoPort, Inc. - Phase II, H2 2011
- XenoPort, Inc. - Pre-Clinical, H2 2011
- XenoPort, Inc. - Pipeline By Therapeutic Class, H2 2011
- XenoPort, Inc. - Pipeline By Target, H2 2011
- XenoPort, Inc. - Pipeline By Route of Administration, H2 2011
- XenoPort, Inc. - Pipeline By Molecule Type, H2 2011
- XenoPort, Inc. - Recent Pipeline Updates, H2 2011
- XenoPort, Inc. - Discontinued Pipeline Products, 2010
- XenoPort, Inc., Deals Summary
- XenoPort Secures $25 Million In Series D Financing
- XenoPort Secures $37 Million In Financing
- XenoPort Amends Its Agreement With GlaxoSmithKline For Horizant
- XenoPort Enters Into Co-Promotion Agreement With GlaxoSmithKline For Solzira
- GlaxoSmithKline Enters Into An Agreement With XenoPort
- XenoPort Enters Into A Co-Development Agreement With Pfizer
- XenoPort Enters Into Licensing Agreement With Xanodyne
- Astellas Pharma Enters Into Licensing Agreement With XenoPort
- XenoPort Prices An Underwritten Public Offering Of $31 Million
- XenoPort Completes Public Offering Of $55 Million
- Xenoport Completes Private Placement Of $40 Million
- XenoPort Completes Public Offering Of $78.9 Million
- XenoPort Completes Initial Public Offering Of $52.6 Million
- List of Figures
- XenoPort, Inc. - Pipeline by Therapy Area and Indication, H2 2011
- XenoPort, Inc. - Pipeline by Stage of Development, H2 2011
- XenoPort, Inc. - Monotherapy Products in Pipeline, H2 2011
- XenoPort, Inc. - Pipeline By Therapeutic Class, H2 2011
- XenoPort, Inc. - Pipeline By Molecule Type, H2 2011
Share this report
Other tasks Related Markets Pharmaceuticals Company Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
